ESR1 and breast carcinoma: ESR1 A908G mutation-positive breast cancer was significantly associated with longer duration and recent use of OCs and with a first-degree family history of breast cancer, suggesting that OCs may interact with the ESR1 A908G mutant receptor in the development of some breast tumors.